Sagent Pharmaceuticals Launches Pamidronate Disodium Injection

SCHAUMBURG, Ill., Jan. 19 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has launched pamidronate disodium injection in single-dose vials containing 30 mg per 10 mL and 90 mg per 10 mL.  Pamidronate disodium injection, the generic alternative of Novartis Pharmaceutical Company's Aredia®, is a bone resorption inhibitor.  The 2008 U.S. market for pamidronate disodium approximated $17 million, according to IMS data.

"Pamidronate is an important adjunctive therapy for cancer patients for the treatment of chemotherapy-associated osteoporosis," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "It will be a valuable addition to Sagent's oncolytic and supportive care product line, and we believe we are well positioned to serve this market."

About Pamidronate Disodium Injection

Pamidronate disodium is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Secondly, pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget's disease of bone. Thirdly, it is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.  Sagent currently has more than 200 products in development.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.  

SOURCE Sagent Pharmaceuticals, Inc.